Previous 10 | Next 10 |
Berkshire Hathaway's 13F stock portfolio value decreased from ~$364B to ~$300B. Their largest three holdings are at ~60% of the entire portfolio. Berkshire Hathaway increased Occidental Petroleum, Ally Financial and Paramount Global while decreasing STORE Capital and General Motor...
Berkshire Hathaway ( NYSE: BRK.B ) ( NYSE: BRK.A ) increased its stakes in Ally Financial ( NYSE: ALLY ), Occidental Petroleum ( NYSE: OXY ), Activision Blizzard ( NASDAQ: ATVI ), Markel ( NYSE: MKL ), and McKesson ( NYSE: MCK ) an...
Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...
Image source: The Motley Fool. Royalty Pharma plc (NASDAQ: RPRX) Q2 2022 Earnings Call Aug 04, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Royalty Pharma plc (RPRX) Q2 2022 Earnings Call Transcript
Royalty Pharma plc (RPRX) Q2 2022 Earnings Conference Call August 4, 2022, 8:00 am ET Company Participants George Grofik - SVP, Head, IR & Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP & Head, Research & Investments Terry...
The following slide deck was published by Royalty Pharma plc in conjunction with their 2022 Q2 earnings call. For further details see: Royalty Pharma plc 2022 Q2 - Results - Earnings Call Presentation
Strong growth in net cash provided by operating activities and Adjusted Cash Receipts (1) Announced transactions of up to $2.5 billion year-to-date, including $1.7 billion in upfront payments Increased 2022 guidance: Adjusted Cash Receipts (1) expected to...
Royalty Pharma press release ( NASDAQ: RPRX ): Q2 Non-GAAP EPS of -$2.68. Revenue of $36.5M (+33.7% Y/Y) AYVAKIT® (avapritinib) net product revenues representing 20 percent AYVAKIT revenue growth from Q1 2022 Company anticipates approximately $180M to $200M in...
Royalty Pharma ( NASDAQ: RPRX ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.78 and the consensus Revenue Estimate is $533.9M Over the last 3 months, EPS estimates have seen 0 upward revisi...
This Buffett holdings list from Kiplinger first appeared on 5/17/22 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire batch. Here is your update from 7/18/22 YCharts data. 32 of 49 current Berkshire Hathaway-owned stocks pay dividends. As of 7/18/22, the top ten ra...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...